TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Benzinga Logo Benzinga By Prnewswire
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

A study published in PLOS One demonstrates that IceCure's Cryoablation System combined with radiation therapy achieved a 92% disease-specific 5-year survival rate for stage I non-small cell lung cancer patients with tumors ≥2 cm.

Insights
ICCM   positive

The study showed highly promising results with 92% 5-year disease-specific survival, 74% overall survival rate, and no treatment-related mortality, which significantly validates the company's medical technology and potential market impact